Danusertib, an aurora kinase inhibitor

Author： Meulenbeld Hielke J Mathijssen Ron HJ Verweij Jaap de Wit Ronald de Jonge Maja JA

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.3, 2012-03, pp. : 383-393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

By Kamei Hiroko Jackson Robert Zheleva Daniella Davidson Fordyce

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 37, Iss. 4, 2010-08 ,pp. : 407-434

Springer Publishing Company

Access to resources Recommend Favorite

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 –– 10)

By Cheung Chun Hei Antonio Coumar Mohane Selvaraj Chang Jang-Yang Hsieh Hsing-Pang

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 857-884

Informa Healthcare

Access to resources Recommend Favorite

Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor

Drug Metabolism Letters, Vol. 5, Iss. 4, 2011-12 ,pp. : 290-297

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)

Drug Metabolism Letters, Vol. 7, Iss. 2, 2014-05 ,pp. : 96-104

Bentham Science Publishers

Access to resources Recommend Favorite

Update on aurora kinase targeted therapeutics in oncology

By Green Myke R Woolery Joseph E Mahadevan Daruka

Expert Opinion on Drug Discovery, Vol. 6, Iss. 3, 2011-03 ,pp. : 291-307

Informa Healthcare

Access to resources Recommend Favorite